Doubling Down on Mutant RAS Can MEK or Break Leukemia
- PMID: 28235190
- DOI: 10.1016/j.cell.2017.02.013
Doubling Down on Mutant RAS Can MEK or Break Leukemia
Abstract
Targeting of the RAS pathway has long been a critical therapeutic challenge in oncology. Burgess et al. examine how the relative expression of mutant and wild-type KRAS modulates clonal fitness and sensitivity to MEK inhibitors in a model of KrasG12D mutant acute myeloid leukemia and propose its use as a predictive biomarker.
Copyright © 2017 Elsevier Inc. All rights reserved.
Comment in
-
KRAS Allelic Imbalance Enhances Fitness and Modulates MAP Kinase Dependence in Cancer.Cell. 2017 Feb 23;168(5):817-829.e15. doi: 10.1016/j.cell.2017.01.020. Epub 2017 Feb 16. Cell. 2017. PMID: 28215705 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous